IRMA-2) tended to present a less favorable RR in patients receiving ARB-II, there was no evidence of significant heterogeneity. Sensitivity analysis was concordant and we found no publication bias.

The unexpected ROADMAP study5 findings on increased cardiovascular-cause mortality in patients receiving olmesartan conflicts with recent trials, principally, the ONGoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET)6 that included 9612 patients with diabetes and reported telmisartan had a beneficial effect similar to that of ramipril—which had previously been shown to reduce myocardial infarction and mortality. It has been argued that some of the excess events occurred in patients with previous ischemic heart disease and in patients in whom olmesartan induced a minimum hypotensive effect or a substantial reduction in blood pressure, raising once more the controversial "J curve" issue with respect to mortality and ischemic heart disease.5,6

We conclude that although previous studies have adequately shown that ARB-II use slows kidney disease in a range of patients with type 2 diabetes with different degrees of vascular disease, the present meta-analysis shows no benefits but nor does it show any harm to patients’ global survival. Further studies will need to determine whether the conflicting ROADMAP study5 results are a cause for concern because they reflect a specific effect of olmesartan—which cannot be discounted—or simply a chance finding. This raises the interesting question as to whether microalbuminuria remains a good intermediate variable to predict cardiovascular outcomes.

Luciano Consuegra-Sánchez, a,∗ Juan Sanchis, b Julio Núñez, b José Domingo Cascón, a Manuel Villegas, a and Francisco Picó a

aServicio de Cardiología, Hospital Universitario del Rosell, Cartagena, Murcia, Spain
bServicio de Cardiología, Hospital Clínico de Valencia, Valencia, Spain

*Corresponding author: E-mail address: lconsue@gmail.com (L. Consuegra-Sánchez).

Available online 12 August 2011

REFERENCES


doi: 10.1016/j.escardio.2011.05.028
factor-like domains. It would be a potentially pathogenic nonsense mutation, according to the revised Ghent criteria. The mutation is located in exon 54, in the 3' region, where 37% of the mutations of FBN1 have been described.

Initially, we studied the presence of the mutation and of the two uncertain variants in the parents of the patient, with the unexpected detection of the same mutation in his mother, who was apparently healthy. In his father (age: 53 years; height: 169 cm), who had a normal physical examination, electrocardiogram and echocardiogram, we detected two variants of uncertain significance. The examination of his mother (age: 50 years; height: 160 cm) revealed marked kyphoscoliosis, abdominal hypotonia and dural ectasia in the magnetic resonance (MR) study. The results of the ophthalmologic examination and transthoracic echocardiogram were normal. Subsequently, his four sisters underwent a molecular study and physical examination. In two of them (NDC and MMDC), the same pathogenic mutation was detected, and in the other two (LDC and ABDC), only the two variants of uncertain significance were observed (Fig. 2). In the examination of NDC (age: 23 years; height: 172 cm), we detected pectus carinatum, arachnodactyly, positive thumb and wrist signs and marked hyperlaxity. Magnetic resonance imaging demonstrated mild scoliosis, as well as dural ectasia at the lumbosacral level. The results of the ophthalmologic examination and echocardiogram were normal. The other three healthy sisters refused to undergo the examination, although MMDC, a carrier of the mutation, had scoliosis.

Unexpectedly, the molecular analysis enabled us to identify three healthy relatives in whom the correct diagnosis had been overlooked for years.

The findings in this family lead us to several conclusions: a) the genetic study should commence with the most severely affected patients and, if a causative mutation is detected, should be continued with relatives; b) taking into account the morbidity and mortality rates in patients with MFS, early diagnosis is important so that appropriate medical and surgical management can be undertaken;2 the recently revised international consensus guidelines for diagnostic criteria2 are valuable for this purpose and, in cases of minimal expression, the genetic diagnosis may not change the clinical management a great deal, but it will permit reproductive options and aid in the evaluation of other relatives;3 c) the molecular study in relatives, a priori with a 50% risk of being affected, makes it possible to identify those with a predisposition to the disease and, moreover, results in a savings in periodical checkups in the case they do not have the mutation; d) MR enables the identification of dural ectasia, present in 90% of the patients with MFS, with a high diagnostic specificity, as has been pointed out in the revision of the Ghent criteria;2 e) special care should be taken in the transmission of the information since, in some cases, the situation is similar to that of the predictive analyses; f) with respect to the variability in expression, Van Dijk et al.4 pointed out that additional trans-acting mutations in FBN1 could play a role as modifiers that would explain the intrafamilial variability; our findings could strengthen this hypothesis since we detected two variants that, when they accompany the mutation, are associated with a more severe phenotype, and that may play a role as modifiers of the phenotype; g) as Comeglio et al. have pointed out,5 it is essential that the scientific community identify the largest possible number of mutations in order to further clarify the causative or modifying effects of similar mutations, a circumstance that would aid in genetic counseling, to define the probable diagnosis and to control decisions made in patient management; and h) if genetic studies are not available, clinical evaluation of relatives is indispensable after a diagnosis of hereditary heart disease in a proband.

Aránzazu Díaz de Bustamante, a, b Eva Ruiz-Casares, b M. Teresa Darnaude, a Teresa Peruchó, b and Gabriel Martínez-Quesada c

aUnidad de Genética, Hospital Universitario de Móstoles, Madrid, Spain
bLaboratorio de Genética, Genyca Innova, Majadahonda, Madrid, Spain
cServicio de Medicina Interna, Hospital Universitario de Móstoles, Móstoles, Madrid, Spain

* Corresponding author:
E-mail addresses: arandiazbus@yahoo.es, adiazb.hmtl@salud.madrid.org (A. Díaz De Bustamante).

Available online 12 August 2011

REFERENCES


doi: 10.1016/j.jrec.2011.05.031